Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg, 3 Dispensers x 28 Tablets, Barr Laboratories, Inc., Pomona, NY NDC 0555-9051-67
Published July 23, 2014 · Recall initiated: June 17, 2014
Summary
FDA records drug Class III recall D-1439-2014, published July 23, 2014 and initiated June 17, 2014. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 5265 blister packs; Lot: Lot 33805449A, Exp. 12/14. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: out of specification impurity test results.
What to do
Voluntary: Firm initiated · Letter
Get an email if VELIVET has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- VELIVET
- Manufacturer
- Teva Pharmaceuticals USA
- Distributor
- Nationwide
- Lot
- Lot 33805449A, Exp. 12/14
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAKariva (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets 0.15 mg/0.02 mg and 0.01 mg, 6 CyclicJuly 23, 2014
- FDATriamcinolone Acetonide Lotion USP, 0.1%, 60 mL Bottle, Rx Only, For Dermatologic Use Only, Not for OphthalmicJuly 23, 2014
- FDAMircette (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets 0.15 mg/0.02 mg and 0.01 mg, 6 CyclicJuly 23, 2014
- FDATriamcinolone Acetonide Lotion USP, 0.025%, 60 mL Bottle, Rx Only, For Dermatologic Use Only, Not forJuly 23, 2014
- FDAApri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, RxJuly 23, 2014
- FDAChloraPrep With Tint, 2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), 26 mLJuly 23, 2014
Questions about this recall
Was Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg, 3 Dispensers x 28 Tablets, Barr Laboratories, Inc., Pomona, NY NDC 0555-9051-67 recalled?
Yes. FDA published recall D-1439-2014 on July 23, 2014. Reported hazard: Failed Impurities/Degradation Specifications: out of specification impurity test results.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: VELIVET.